This Beaten-Down Growth Stock Could Soar 30%, According to Wall Street

Grail’s Galleri blood test missed its primary endpoint in the NHS England trial, helping drive the stock down sharply and prompting Canaccord to cut its price target from $105 to $80. The company still trades around $60, below its Jan. 22, 2026 record high of $116.06, while the FDA approval timeline remains uncertain. Revenue rose from $93 million in 2023 to $147 million in 2025, but analysts still model losses of $485 million in 2027 and $481 million in 2028.

Analysis

The market is still pricing GRAL like a binary regulatory win, but the trial failure shifts the debate from “when” to “if” for broad reimbursement. That matters because the current revenue base is mostly early-adopter, cash-pay demand, which is a narrow and expensive customer funnel; without coverage, the company has to spend into a ceiling rather than a runway. The bigger second-order effect is that every additional negative datapoint likely raises the cost of capital for follow-on commercialization, which can matter more than the near-term revenue line for a pre-scale diagnostics story.

The read-through for ILMN is modestly positive only in the sense that a weaker stand-alone GRAL narrative lowers the odds of a near-term value leak from the spin. But a prolonged stall in MCED adoption also delays the broader validation of liquid-biopsy economics, which could slow enthusiasm around adjacent diagnostics platforms, especially anything dependent on payer adoption rather than pure assay performance. In other words, the market may be underestimating how much of the bull case required a clean reimbursement flywheel, not just better science.

The most important contrarian point is that this is not yet a terminal clinical failure; it is a commercialization failure. The distinction matters over 12-24 months: if subgroup data can be converted into a narrower label or targeted screening use-case, the equity can re-rate sharply even without the original “screen everybody” thesis. But until there is either regulatory progress or clearer health-economic proof, the stock likely trades as a high-beta financing event, not a platform compounding story.

Key Decisions for Investors

• Avoid initiating long GRAL here; if forced to express the view, prefer a small short or put spread into any post-rally strength over the next 1-3 months, targeting a downside move back toward the pre-gap trading range if regulatory timing slips again.
• If already long GRAL, reduce exposure and keep only a pilot position; use call spreads instead of stock to cap capital-at-risk while preserving upside to a narrow-label or FDA surprise over 6-12 months.
• Consider ILMN as a relative-value beneficiary versus GRAL if the market continues to punish the spin-out ecosystem more than fundamentals justify; look for long ILMN / short GRAL on any widening valuation gap over the next quarter.
• Do not chase the stock on “optional regulatory upside” alone; wait for either a clearer FDA path or third-party reimbursement evidence before reconsidering a long, since the catalyst window now looks more like 12-24 months than weeks.